LOGIN  |  REGISTER
Recursion
Assertio

Addus HomeCare to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference

March 05, 2024 | Last Trade: US$112.38 2.11 1.91

FRISCO, Texas / Mar 05, 2024 / Business Wire / Addus HomeCare Corporation (Nasdaq: ADUS), a provider of home care services, today announced that Dirk Allison, Chairman, President and Brad Bickham, President and Chief Operating Officer, will participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference on March 12, 2024.

In connection with the virtual conference, there will be a live broadcast and replay of the Company’s presentation available under the Investor Relations section of the Company’s website, www.addus.com, starting at 11:20 a.m. Eastern Time / 10:20 a.m. Central Time on Tuesday, March 12, 2024. An online replay will also be available on the Company’s website for one month, beginning approximately one hour following the conclusion of the live broadcast.

About Addus HomeCare

Addus HomeCare is a provider of home care services that primarily include personal care services that assist with activities of daily living, as well as hospice and home health services. Addus HomeCare’s consumers are primarily persons who, without these services, are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. Addus HomeCare’s payor clients include federal, state, and local governmental agencies, managed care organizations, commercial insurers, and private individuals. Addus HomeCare currently provides home care services to over 49,000 consumers through 217 locations across 22 states. For more information, please visit www.addus.com.

Assertio

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page